MedTrace Logo

Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection

NCT00196638 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2006-08-29

No results posted yet for this study

Summary

Treatment of acute primary HIV infection may improve long-term outcome. However, optimal treatment is still debated. The ANRS 112-INTERPRIM trial evaluates three different therapeutical strategies, combining permanent or intermittent HAART and a cytokine, interferon alpha, in order to determine which combination allows the best control of HIV viremia after 24 weeks of antiretroviral treatment interruption

Conditions

  • HIV Infections
  • Primary Acute Infection

Interventions

DRUG

Antiretroviral combination (drugs)

DRUG

Pegylated Interferon alpha (drug)

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • French National Agency for Research on AIDS and Viral Hepatitis

    lead OTHER_GOV

Principal Investigators

  • Dominique Emilie, MD · Hôpital Antoine Béclère, Clamart, France

  • Genevieve Chene, MD, PhD · INSERM U593, Bordeaux, France.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Completion
2006-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00196638 on ClinicalTrials.gov